Home / Resources / Generics Bulletin Top 50 Ranking for 2024
Generics Bulletin Top 50 Ranking for 2024

This eBook compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

Generics Bulletin Top 50 Ranking for 2024
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
Generic Drug Manufacturing
Generics Bulletin
グローバルジェネリック医薬品、バイオシミラー、付加価値のある医薬品業界に関する他の追随を許さないニュースと分析
KOL thought leader interview
In Vivo
ライフサイエンスの意思決定者のためのインタビュー、分析、重要な洞察
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析

Related resources

3D model of a RNA strand.
JUL 30, 2024
Report
商業化支援サービス

Q2 2024 Gene, Cell, + RNA Therapy Landscape Report

In this report, by Citeline and the American Society of Gene & Cell Therapy (ASGCT), new approvals in Q2 2024 were focused on the RNA landscape.

Citeline professional presenting the Q3 2024 Outlook Report provided by Biomedtracker.
JUL 08, 2024
Report
商業化支援サービス

Q3 2024 Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q3 2024.

View all